Plate 500 of 545Verified

Scopolamine

PubChem records this structure as Boro-Scopol.

Also known asBoro-Scopol · Scopace · Hyoscine · (-)-Hyoscine · Scopine tropate · Transderm-Scop · (-)-Scopolamine · Scopine (-)-tropate

[(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate

PubChem CID: 3000322
ChEMBL: CHEMBL569713
Measurements: 22
InChIKey: STECJAGHUSJQJN-USLFZFAMSA-N

I · Summary

What is known

Published passages, each quoted whole and attributed to the database that published it. Two blocks are written here rather than quoted, and both say so where they stand: the synthesized summary at the top, which may draw only on the passages beneath it, and the history note, which cites the works it came from. Every claim in either carries a marker to its source.

What it is

Scopolamine is a tropane alkaloid that is the (S)-tropic acid ester of 6beta,7beta-epoxy-1alphaH,5alphaH-tropan-3alpha-ol. It has a role as a metabolite, an antidepressant, a muscarinic antagonist, a mydriatic agent, an antiemetic, an antispasmodic drug, an anaesthesia adjuvant and an adjuvant. It is an epoxide, a propanoate ester, a tropane alkaloid and a tertiary amino compound. It is functionally related to a (S)-tropic acid. It is a conjugate base of a scopolamine(1+).
ChEBI
LSM-4015 has been reported in Scopolia parviflora, Duboisia leichhardtii, and other organisms with data available.
LOTUS - the natural products occurrence database
See also: Scopolamine (annotation moved to); Scopolamine Hydrobromide (annotation moved to); Scopoline (annotation moved to) ... View More ...
PubChem

How it acts

Muscarinic acetylcholine receptor M1 antagonistANTAGONISTPMID 23615033

[Acetylcholine] (ACh) is a neurotransmitter that can signal through ligand-gated cation channels (nicotinic receptors) and G-protein-coupled muscarinic receptors (mAChRs). ACh signalling via mAChRs located in the central nervous system (CNS) and periphery can regulate smooth muscle contraction, glandular secretions, heart rate, and various neurological phenomena such as learning and memory. mAChRs can be divided into five subtypes, M1-M5, expressed at various levels throughout the brain. Also, M2 receptors are found in the heart and M3 receptors in smooth muscles, mediating effects apart from the direct modulation of the parasympathetic nervous system. While M1, M3, and M5 mAChRs primarily c……
DrugBank
Scopolamine is an anticholinergic belladonna alkaloid that, through competitive inhibition of muscarinic receptors, affects parasympathetic nervous system function and acts on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Formulated as a patch, scopolamine is released continuously over three days and remains detectable in urine over a period of 108 hours. Scopolamine is contraindicated in angle-closure glaucoma and should be used with caution in patients with open-angle glaucoma due to scopolamine's ability to increase intraocular pressure. Also, scopolamine exhibits several neuropsychiatric effects: exacerbated psychosis, seizures, seizure-like, and other ps…
DrugBank

Behavior carries the pharmacological classes and the acute-effect durations, with plasma half-life kept separate from duration of effect.

History, discovery and cultural use

— Not in this archive. PubChem, ChEMBL and the Human Protein Atlas publish pharmacology, regulation and toxicology, and none of them publishes a heading for when Scopolamine was first made, by whom, or how it has been used. That is a gap in the databases this site reads and not a gap in the literature — the history of these compounds is written, at length and under peer review, in the works below. This site does not summarize them; it says where they are. Where a published passage above happens to touch origin or traditional use, it appears inside the entry that carries it.

Histories of this field

Scholarship on psychedelics generally, not on Scopolamine specifically. Whether any of these treats this compound is a question for the book, not for this page.

Mescaline: A Global History of the First Psychedelic
Traces mescaline and the peyote and San Pedro cacti from pre-Columbian ritual use through nineteenth-century chemistry to twentieth-century psychiatry and the counterculture.
Jay M. Mescaline: A Global History of the First Psychedelic. Yale University Press, New Haven and London; 2019. ISBN 9780300231076.
Expanding Mindscapes: A Global History of Psychedelicsopen access
Essays on the international and cross-cultural history of psychedelic science, deliberately decentring the standard North American and European account.
Dyck E, Elcock C, editors. Expanding Mindscapes: A Global History of Psychedelics. The MIT Press, Cambridge MA; 2023. ISBN 9780262546935 (paper), 9780262376891 (open access). doi:10.7551/mitpress/14417.001.0001.
Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers
Botany, ethnography and chemistry of the principal hallucinogenic plants, by the founder of modern ethnobotany and the chemist who first synthesized LSD.
Schultes RE, Hofmann A, Rätsch C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. 2nd ed. Healing Arts Press, Rochester VT; 2001. ISBN 9780892819799.
Psychonauts: Drugs and the Making of the Modern Mind
The tradition of scientific self-experimentation with psychoactive drugs, and its part in the emergence of psychology and of modernism.
Jay M. Psychonauts: Drugs and the Making of the Modern Mind. Yale University Press, New Haven; 2023. ISBN 9780300257946.
Ancient Psychoactive Substances
Archaeological and bioarchaeological evidence for psychoactive plant use across the ancient world.
Fitzpatrick SM, editor. Ancient Psychoactive Substances. University Press of Florida, Gainesville; 2018. ISBN 9780813056708.
History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders
A chapter tracing psychedelic and entactogen research from earlier ritual use through the mid-century research period to current clinical trials.
Stroud C, Posey Norris SM, Matney C, editors. History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders. In: Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. National Academies Press, Washington DC; 2022. NBK587225.
Workshop proceedings record what participants said; they are not a consensus statement of the National Academies.
Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions
Peer-reviewed review covering the isolation, synthesis, pharmacology and ritual use of peyote and mescaline.
Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology 12(3):184–194; 2019. doi:10.2174/1874467211666181010154139.

Institutional archives

Heffter Research Institute Funds and coordinates clinical research on psilocybin, and keeps records of the studies it has supported since 1993. Sponsors the research it archives.
Multidisciplinary Association for Psychedelic Studies (MAPS) Sponsors clinical research, chiefly on MDMA-assisted therapy, and publishes an archive of historical and contemporary documents. A sponsor and an advocacy organization, not a disinterested archive; its clinical programme has a commercial arm.

The rest of this dossier

Affinity — 22 measurements in this archive, equilibrium constants kept apart from functional readouts.
Toxicology — nothing published for Scopolamine. An absent record is an absence of study, not evidence of safety.
Legal — no DEA record is held here — which is not a finding that this compound is uncontrolled.

Passages via PubChem descriptive sections, aggregating DrugBank, LiverTox, FDA, DEA, HSDB, EPA. Each is quoted whole and attributed to the database that published it. The only prose written here about Scopolamine is the history note, which says so on its face and carries a reference for every claim in it.

II · Identity

Structure and descriptors

Descriptors are computed here with RDKit from the structure PubChem returns — not from the archive's stored copy, so an edited local structure cannot reach this table.

2D structural depiction of Scopolamine — Depiction served by PubChem for CID 3000322. Not redrawn here, so the picture and the identity come from the same record.

Formula: C17H21NO4R
Molecular weight: 303.36g/molR
Exact mass: 303.1471DaR
cLogP: 0.92R
TPSA: 62.3Å²R
H-bond donors: 1R
H-bond acceptors: 5R
Rotatable bonds: 4R
Aromatic rings: 1R
Heavy atoms: 22R
Fraction sp³: 0.588R
Formal charge: 0R

Computed with RDKit 2025.09.2 from the SMILES returned by PubChem. Audit run 26/09/2026.

Bemis–Murcko scaffold

O=C(Cc1ccccc1)OC1C[C@@H]2N[C@H](C1)[C@H]1O[C@H]12

Shared with Anisodine. All families

III · Behavior

Behavioral summary

Class, mechanism, and the duration of acute effects — each quoted from the record or trial that publishes it. Duration of effects and plasma half-life are shown separately, because they are different quantities and diverge by a factor of three or four.

Classification

Duration of acute subjective effects

—

No controlled human trial reporting a duration for this compound is cited here. The archive does hold onset and duration ranges for it, inherited from an earlier build, but their source column is empty and so they cannot be shown. A duration is not inferred from a chemical relative.

Plasma elimination half-life

How fast the body clears the drug — not how long the effects last. The two diverge sharply: LSD is cleared with a half-life of about 2.6 h while its subjective effects run 8–12 h.

~220 min

“Elimination half-life was approximately 220 minutes”

Subcutaneous administration.Ebert U et al., Journal of clinical pharmacology 1998. PMID 9725548

Primary pharmacological drivers

Muscarinic acetylcholine receptor M1 antagonist23615033

Mechanism, as published

Quoted verbatim from the database named after each passage, never summarized.

[Acetylcholine] (ACh) is a neurotransmitter that can signal through ligand-gated cation channels (nicotinic receptors) and G-protein-coupled muscarinic receptors (mAChRs). ACh signalling via mAChRs located in the central nervous system (CNS) and periphery can regulate smooth muscle contraction, glandular secretions, heart rate, and variou……
DrugBank
Scopolamine is an anticholinergic belladonna alkaloid that, through competitive inhibition of muscarinic receptors, affects parasympathetic nervous system function and acts on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Formulated as a patch, scopolamine is released continuously over three days and remai…
DrugBank

IV · Clinical

Clinical description

Where this compound's substance class sits in ICD-11 and DSM-5-TR, and how much of the recorded literature speaks to each domain of a mental status examination.

No diagnostic chapter is shown for this compound. Either PubChem records no MeSH pharmacological class for it, or the class it records is not one of the substance classes ICD-11 gives a chapter to. Inferring a chapter from the compound’s name or its binding profile would be a diagnosis this archive is in no position to make.

How much has been written about each domain

The clinical domains, and how many of the records this archive holds for this compound say something under each. What the terms mean, and the word list behind every spoke, are set out in the method.

This measures the literature, not the compound. Each spoke counts how many of the 4 records this archive holds for this compound say something under that domain — 3 at the widest ring. A long spoke means the subject has been written about, not that the effect is strong, and a spoke at the center means nothing here discusses it rather than that nothing happens. The terms behind each domain are listed in the method.

Cognition 3: matched on “cognitiv”, “concentrat”, “memory” · in Pharmacology: Mechanism of Action; Pharmacology: Biological Half-Life; Pharmacology: Pharmacodynamics

VI · Profile

Affinity rosette

The strongest measurement at each of 1 molecular targets. Cell-line and whole-organism screens are excluded here — they carry no affinity — and appear in the table below.

Fig. Radius is pX = −log₁₀(value in M), that is 9 − log₁₀(value in nM), computed from the normalized measurement. Hatched wedges are equilibrium binding constants (K_i, K_d); dashed outlines are functional readouts (IC₅₀, EC₅₀, AC₅₀, potency), which answer a different question and are not pooled with them. Rings mark whole pX units from 5 to 10, labeled every second ring in the gutter at the top. Where a target carries several measurements, the strongest is drawn.

VII · Toxicology

Toxicological profile

What has been measured, and what has been published — kept apart, and neither scored. There is no risk rating on this page; the archive once carried one, identical for every compound, produced by a stub.

Measured in this archive

Assays that bear on toxicity, drawn from the same ChEMBL records as everything else on this page. They are measurements of what a compound binds or does to cells — not verdicts about what it does to a person.

No hERG, cytochrome, cytotoxicity or transport measurement exists for Scopolamine in this archive.

Published toxicology

— None. The toxicology databases this site reads — HSDB, RTECS and LiverTox, by way of PubChem — hold no record for Scopolamine. They index compounds that have been studied for decades, so most of this archive has no entry. An absent record is an absence of study, not evidence of safety.

Published passages via PubChem toxicology sections, aggregating Hazardous Substances Data Bank (HSDB), RTECS, LiverTox. No figure on this page is scored, ranked or combined into a risk level.

VIII · Evidence

Every measurement

One row per published value. The identifier in the last column resolves to the ChEMBL assay record it was read from.

Equilibrium binding constants 19

Ki and Kd — a concentration at equilibrium. Directly comparable across rows at the same target.

Target	Class	Type	Value (nM)	pX	Organism	Assay
Muscarinic acetylcholine receptor	Cholinergic receptors	Ki	0.080	10.10	Rattus norvegicus	CHEMBL748441
M4	Unclassified	Ki	0.140	9.85	RAT	PMID 9834968
M3	Unclassified	Ki	0.182	9.74	RAT	PMID 2250662
M1	Unclassified	Ki	0.186	9.73	RAT	PMID 2250662
M4	Unclassified	Ki	0.210	9.68	PORCINE	PMID 9834968
M4	Unclassified	Ki	0.224	9.65	RABBIT	PMID 2250662
M4	Unclassified	Ki	0.380	9.42	BOVINE	PMID 9834968
M1	Unclassified	Ki	0.410	9.39	Bos taurus	CHEMBL745466
M2	Unclassified	Ki	0.440	9.36	HUMAN	PMID 1346637
M3	Unclassified	Ki	0.440	9.36	HUMAN	PMID 1346637
M1	Unclassified	Ki	0.530	9.28	Rattus norvegicus	CHEMBL745924
M4	Unclassified	Ki	0.800	9.10	HUMAN	PMID 1346637
M4	Unclassified	Ki	0.933	9.03	Chick	PMID 2250662
M1	Unclassified	Ki	1.10	8.96	HUMAN	PMID 1346637
M2	Unclassified	Ki	1.41	8.85	RAT	PMID 2250662
M2	Unclassified	Ki	2.00	8.70	HUMAN	PMID 1346637
M5	Unclassified	Ki	2.07	8.68	HUMAN	PMID 1346637
M2	Unclassified	Kd	3.00	8.52	Rattus norvegicus	CHEMBL745476
M2	Unclassified	Ki	4.57	8.34	Rattus norvegicus	CHEMBL744097

Functional readouts 3

IC₅₀, EC₅₀, AC₅₀ and potency. Assay-dependent, and not interchangeable with a binding constant.

Target	Class	Type	Value (nM)	pX	Organism	Assay
Muscarinic acetylcholine receptor	Cholinergic receptors	IC50	4.00	8.40	Rattus norvegicus	CHEMBL744136
Muscarinic acetylcholine receptor	Cholinergic receptors	IC50	4.00	8.40	Rattus norvegicus	CHEMBL744138
Muscarinic acetylcholine receptor	Cholinergic receptors	IC50	10.00	8.00	Rattus norvegicus	CHEMBL746568

P: PubChem
C: ChEMBL
R: Computed here with RDKit
D: Derived here from the stored measurement

IX · Trials

Registered clinical trials

Studies filed with ClinicalTrials.gov that name this compound as an intervention. A registered trial is a protocol, not a result — status and enrollment are printed beside every row, and withdrawn studies are counted rather than hidden.

97T

Registered studies

Open or ongoing

94T

With a phase recorded

By phase

A study may carry two phase codes at once, so these count studies bearing each phase and do not sum to the total.

Early phase 15
Phase 118
Phase 218
Phase 313
Phase 422
Not applicable24

By status

The registry’s own status for each record. Withdrawn and terminated studies are counted here rather than hidden — a stopped trial is part of what is known.

Completed64
Unknown status15
Terminated8
Recruiting3
Withdrawn3
Not yet recruiting2
Enrolling by invitation1
Suspended1

The 25 most recently started, of 97

Newest first by start date. Each identifier opens the registry record it came from; the title is the sponsor’s own, quoted.

NCT07271303Not yet recruiting · Not applicable
A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures
Enrollment
74Testimated
Started
2026-02-01
Sponsor
Shanghai Jiao Tong University School of Medicine
Conditions Painless Gastrointestinal Endoscopy
Matched “Hyoscine” in the study’s intervention “Hyoscine Butylbromide”
NCT07814976Recruiting · Not applicable
Hyoscine Butylbromide During Transcystic Papillary Balloon Dilation for Choledocholithiasis
Enrollment
50Testimated
Started
2026-01-04
Sponsor
Riga East Clinical University Hospital
Conditions Choledocholithiasis · Common Bile Duct Stones
Matched “Hyoscine” in the study’s intervention “Hyoscine Butylbromide”
NCT07383571Completed · Not applicable
Oral Hyoscine vs Lidocaine-Prilocaine Spray vs Placebo for HSG Pain Relief
Enrollment
102Tactual
Started
2025-10-03
Sponsor
Cairo University
Conditions Hysterosalpingography
Matched “Hyoscine” in the study’s intervention “Oral Hyoscine butylbromide and Placebo Spray”
NCT07423923Enrolling by invitation · Early phase 1
Representation of Spatiotemporal Information in Human Episodic Memory and Navigation
Enrollment
15Testimated
Started
2025-04-01
Sponsor
University of Arizona
Conditions Scopolamine or Placebo · Schema to Organize Memory or no Schema
Matched “Scopolamine” in the study’s intervention “Scopolamine”
NCT06014385Withdrawn · Phase 1
PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor
Enrollment
0Tactual
Started
2025-03
Sponsor
Yale University
Conditions Muscarinic Receptor Occupancy
Matched “Scopolamine” in the study’s intervention “Scopolamine”
NCT06398054Not yet recruiting · Phase 4
A Study to Investigate the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy
Enrollment
190Testimated
Started
2024-10-01
Sponsor
ASST Fatebenefratelli Sacco
Conditions Pain
Matched “Hyoscine” in the study’s intervention “Hyoscine N-Butil Bromide”
NCT06056869Unknown status · Not applicable
Effect of Hyoscine- Bromide on Duration of the First Stage of Labor
Enrollment
60Testimated
Started
2023-09-27
Sponsor
Ain Shams University
Conditions Labor
Matched “Hyoscine” in the study’s intervention “hyoscine butylbromide”
NCT07474350Completed · Not applicable
Valethamate Bromide Versus Hyoscine Butyl Bromide in Reducing Labour Duration Among Primigravida
Enrollment
165Tactual
Started
2023-09-01
Sponsor
Federal Teaching Hospital Abakaliki
Conditions Labour Duration · Primigravida
Matched “Hyoscine” in the study’s intervention “Hyoscine butylbromide”
NCT05911126Unknown status · Not applicable
How to Reduce Pain in Patients Undergoing Office Hysteroscopy.
Enrollment
180Testimated
Started
2023-06-13
Sponsor
Cairo University
Conditions Pain
Matched “Hyoscine” in the study’s intervention “Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet”
NCT04666701Withdrawn · Phase 2
Efficacy and Safety of Escócia Association in the Treatment of Acute Pain
Enrollment
0Tactual
Started
2023-02
Sponsor
EMS
Conditions Acute Pain
Matched “Scopolamine” in the study’s intervention “Placebo Scopolamine”
NCT06207539Completed · Early phase 1
Induction of Abortion in the Second Trimester
Enrollment
40Tactual
Started
2022-12-01
Sponsor
Ain Shams Maternity Hospital
Conditions Abortion, Second Trimester
Matched “Hyoscine” in the study’s intervention “hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company”
NCT04999449Completed · Phase 1
Nebulizer Delivery of Intranasal Scopolamine
Enrollment
14Tactual
Started
2022-01-24
Sponsor
Dartmouth-Hitchcock Medical Center
Conditions Scopolamine · Motion Sickness
Matched “Scopolamine” in the study’s intervention “Scopolamine”
NCT04785118Completed · Phase 4
Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia
Enrollment
165Tactual
Started
2021-10-01
Sponsor
Assiut University
Conditions Vomiting
Matched “Hyoscine” in the study’s intervention “Hyoscine N Butylbromide”
NCT04682860Completed · Phase 4
Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide
Enrollment
50Tactual
Started
2021-09-08
Sponsor
Ankara City Hospital Bilkent
Conditions Acute Gastroenteritis · Abdominal Pain
Matched “Hyoscine” in the study’s intervention “Hyoscine N Butylbromide”
NCT04366518Recruiting · Early phase 1
Toward a Computationally-Informed, Personalized Treatment for Hallucinations
Enrollment
35Testimated
Started
2021-07-15
Sponsor
Yale University
Conditions Hallucinations, Auditory · Psychosis
Matched “Scopolamine” in the study’s intervention “Scopolamine”
NCT04211961Completed · Phase 2
Scopolamine in Bipolar Depression
Enrollment
55Tactual
Started
2021-03-23
Sponsor
Dr. Brian Hallahan
Conditions Bipolar Disorder Depression
Matched “Scopolamine” in the study’s intervention “Scopolamine”
NCT04866355Completed · Not applicable
Lumbar Spine Manipulation Versus Pharmacological Therapy in Young Women With Primary Dysmenorrhea
Enrollment
42Tactual
Started
2021-02-28
Sponsor
University of Alcala
Conditions Women With Primary Dysmenorrhea
Matched “Hyoscine” in the study’s intervention “Hyoscine and Ibuprofen”
NCT04240626Completed · Phase 4
Multimodal Analgesia Effect on Post Surgical Patient
Enrollment
60Tactual
Started
2021-01-20
Sponsor
University of California, Davis
Conditions Obesity, Morbid · Surgery · Bariatric Surgery Candidate
Matched “Scopolamine” in the study’s intervention “Scopolamine patch”
NCT06927817Completed · Phase 4
The Effect of Hyoscine-n-butylbromide on Nausea and Pain in Laparoscopic Cholecystectomy
Enrollment
134Tactual
Started
2020-11-15
Sponsor
Saglik Bilimleri Universitesi
Conditions Cholecystitis · Pain · Nausea
Matched “Hyoscine” in the study’s intervention “hyoscine-n-butylbromide, ondansetron”
NCT04391361Unknown status · Phase 2
The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS
Enrollment
30Testimated
Started
2020-11-01
Sponsor
Ruijin Hospital
Conditions Amyotrophic Lateral Sclerosis · Respiratory Function · Scopolamine
Matched “Scopolamine” in the study’s intervention “Scopolamine, atropine, edaravone and dexmedetomidine”
NCT04314713Terminated · Phase 1
A Study to Evaluate the Intramuscular Administration of Scopolamine
Enrollment
32Tactual
Started
2020-06-02
Sponsor
Battelle Memorial Institute
Conditions Medical Countermeasures · Organophosphate Poisoning
Matched “Scopolamine” in the study’s intervention “Scopolamine Hydrobromide Trihydrate”
NCT04349722Completed · Phase 4
The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae
Enrollment
110Tactual
Started
2019-12-01
Sponsor
National University of Malaysia
Conditions Labor Long
Matched “Hyoscine” in the study’s intervention “Hyoscine Butylbromide”
NCT04069078Completed · Phase 4
Hyoscine Butylbromide for Prevention of Bradycardia During Cesarean Section
Enrollment
173Tactual
Started
2019-10-10
Sponsor
Assiut University
Conditions Bradycardia · Spinal Anesthetics Causing Adverse Effects in Therapeutic Use · Cesarean Section Complications
Matched “Hyoscine” in the study’s intervention “Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule”
NCT05594017Recruiting · Early phase 1
Pharmacological Modulation of Brain Oscillations in Memory Processing
Enrollment
60Testimated
Started
2019-08-01
Sponsor
University of Texas Southwestern Medical Center
Conditions Epilepsy · Seizures · Cognitive Impairment, Mild · Memory Disorders · Memory Loss
Matched “Scopolamine” in the study’s intervention “Scopolamine (0.4mg)”
NCT03441217Completed · Not applicable
Hyoscine Butylbromide Effect on Duration of Labor
Enrollment
218Tactual
Started
2019-07-12
Sponsor
Saint Thomas Hospital, Panama
Conditions Labor
Matched “Hyoscine” in the study’s intervention “Hyoscine Butylbromide 20Mg/1mL Injection”

Records from ClinicalTrials.gov (U.S. National Library of Medicine, NIH), API v2. A study is listed against a compound only when a verified name for that compound appears as a whole word in one of the study's own intervention names. A short code must appear as written, and a name the registry uses for something else (Aleph, a vaccine maker) is not matched. Title matches are not accepted. The matched name and the intervention text it matched are shown with every row.

Searched as Scopolamine · Boro-Scopol · (-)-Hyoscine. Run this search at the registry — it returns the unfiltered result, including studies this page rejected as belonging to a different molecule.

A registered trial is a protocol somebody filed with the registry. It is not a result, and nothing on this plate says whether Scopolamine worked.

X · Legal

Controlled-substance status

United States federal scheduling, read from the DEA records this archive holds. Not legal advice, and an absent record is not a finding that a compound is uncontrolled.

No DEA record heldNot the same as unscheduled — see below.

An absent DEA record is not a finding that Scopolamine is legal. It means this archive holds no DEA passage for it. The Controlled Substances Analogue Enforcement Act reaches substances that appear on no schedule by name, and many compounds here are ring-substituted analogues of scheduled drugs. Nothing on this plate should be read as saying a compound may lawfully be made, held or supplied.

United States federal status only. State law differs, and so does the law of every other country — none of it is represented here. Scheduling changes, and this reflects the DEA records held by PubChem descriptive sections when the monograph was last harvested, not necessarily today. This is a record of what a database publishes, not legal advice.

XI · Literature

Sources behind this dossier

The papers this compound's values were read from, ranked by what each contributed. Not a review of the field.

Every paper below is one some value on this page came from — a binding constant, a passage of pharmacology or toxicology, or a measured duration. Each entry says what this archive took from it. Nothing else is claimed about any of them: the title is the study’s own account of itself, and a summary written here would be an assertion with no source behind it.

01
Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells
Bolden C, Cusack B, Richelson E · The Journal of pharmacology and experimental therapeutics 1992
- · 6 measurements at 5 targets (Ki), strongest M2 at 9.36 pX
PMID 1346637
02
Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells
Lazareno S, Buckley NJ, Roberts FF · Molecular pharmacology 1990
- · 5 measurements at 4 targets (Ki), strongest M3 at 9.74 pX
PMID 2250662
03
Muscarinic receptor binding sites of the M4 subtype in porcine lung parenchyma
Chelala JL, Kilani A, Miller MJ et al. · Pharmacology & toxicology 1998
- · 3 measurements at 1 target (Ki), strongest M4 at 9.85 pX
PMID 9834968
04
Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration
Ebert U, Siepmann M, Oertel R et al. · Journal of clinical pharmacology 1998
- · Plasma elimination half-life
PMID 9725548